Because of its rarity, the prevalence of bullous lupus is difficult to estimate, but large cohort studies hypothesize that 0.19-0.41% of patients with SLE develop a bullous lupus manifestation [7]. Case reports associate TNF-alpha inhibitors, interleukin-6 (IL-6) inhibitors, terbinafine, methimazole, and penicillamine with DIBL [2,6,8,9]. Here, IL6 is linked to systemic lupus erythematosus.